##gff-version 3								
##gvf-version 1.10								
##species https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=2697049								
#seqid	#source	#type	#start	#end	#score	#strand	#phase	#attributes
NC_045512.2	.	snp	110	110	.	+	.	ID=ID_0;Name=g.C-156T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=141;ao=131;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C-156T;aa_name=;hgvs_nt=NC_045512.2:g.156C>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.48161764705882354;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	140	140	.	+	.	ID=ID_1;Name=g.C-126T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=269;ao=3;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C-126T;aa_name=;hgvs_nt=NC_045512.2:g.126C>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.011029411764705883;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	205	205	.	+	.	ID=ID_2;Name=g.T-61C;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=262;ao=10;dp=272;sample_size=280;Reference_seq=T;Variant_seq=C;nt_name=g.T-61C;aa_name=;hgvs_nt=NC_045512.2:g.61T>C;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03676470588235294;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	241	241	.	+	.	ID=ID_3;Name=g.C-25T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=271;dp=271;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C-25T;aa_name=;hgvs_nt=NC_045512.2:g.25C>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	351	351	.	+	.	ID=ID_4;Name=R29H;alias=R29H;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:1..180;ro=268;ao=4;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G86A;aa_name=p.R29H;hgvs_nt=NC_045512.2:g.86G>A;hgvs_aa=YP_009724389.1:p.Arg29His;hgvs_alias=YP_009724389.1:Arg29His;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.014705882352941176;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	1059	1059	.	+	.	ID=ID_5;Name=T265I;alias=T85I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C794T;aa_name=p.T265I;hgvs_nt=NC_045512.2:g.794C>T;hgvs_aa=YP_009724389.1:p.Thr265Ile;hgvs_alias=YP_009724389.1:Thr85Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	1593	1593	.	+	.	ID=ID_6;Name=S443F;alias=S263F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=266;ao=6;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C1328T;aa_name=p.S443F;hgvs_nt=NC_045512.2:g.1328C>T;hgvs_aa=YP_009724389.1:p.Ser443Phe;hgvs_alias=YP_009724389.1:Ser263Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.022058823529411766;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	2232	2232	.	+	.	ID=ID_7;Name=A656V;alias=A476V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=227;ao=45;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C1967T;aa_name=p.A656V;hgvs_nt=NC_045512.2:g.1967C>T;hgvs_aa=YP_009724389.1:p.Ala656Val;hgvs_alias=YP_009724389.1:Ala476Val;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.16544117647058823;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	2659	2659	.	+	.	ID=ID_8;Name=K798N;alias=K618N;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=269;ao=2;dp=271;sample_size=280;Reference_seq=G;Variant_seq=T;nt_name=g.G2394T;aa_name=p.K798N;hgvs_nt=NC_045512.2:g.2394G>T;hgvs_aa=YP_009724389.1:p.Lys798Asn;hgvs_alias=YP_009724389.1:Lys618Asn;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007380073800738007;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	2867	2867	.	+	.	ID=ID_9;Name=V868L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=264;ao=7;dp=271;sample_size=280;Reference_seq=G;Variant_seq=T;nt_name=g.G2602T;aa_name=p.V868L;hgvs_nt=NC_045512.2:g.2602G>T;hgvs_aa=YP_009724389.1:p.Val868Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.025830258302583026;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	3037	3037	.	+	.	ID=ID_10;Name=F924F;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=0;ao=271;dp=271;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C2772T;aa_name=p.F924F;hgvs_nt=NC_045512.2:g.2772C>T;hgvs_aa=YP_009724389.1:p.Phe924Phe;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	3247	3247	.	+	.	ID=ID_11;Name=S994R;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=260;ao=11;dp=271;sample_size=280;Reference_seq=T;Variant_seq=G;nt_name=g.T2982G;aa_name=p.S994R;hgvs_nt=NC_045512.2:g.2982T>G;hgvs_aa=YP_009724389.1:p.Ser994Arg;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.04059040590405904;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	3304	3304	.	+	.	ID=ID_12;Name=E1013D;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=267;ao=4;dp=271;sample_size=280;Reference_seq=G;Variant_seq=T;nt_name=g.G3039T;aa_name=p.E1013D;hgvs_nt=NC_045512.2:g.3039G>T;hgvs_aa=YP_009724389.1:p.Glu1013Asp;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.014760147601476014;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	3691	3691	.	+	.	ID=ID_13;Name=E1142D;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=270;ao=2;dp=272;sample_size=280;Reference_seq=A;Variant_seq=C;nt_name=g.A3426C;aa_name=p.E1142D;hgvs_nt=NC_045512.2:g.3426A>C;hgvs_aa=YP_009724389.1:p.Glu1142Asp;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007352941176470588;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	4201	4201	.	+	.	ID=ID_14;Name=M1312I;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=268;ao=4;dp=272;sample_size=280;Reference_seq=G;Variant_seq=T;nt_name=g.G3936T;aa_name=p.M1312I;hgvs_nt=NC_045512.2:g.3936G>T;hgvs_aa=YP_009724389.1:p.Met1312Ile;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.014705882352941176;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	4276	4276	.	+	.	ID=ID_15;Name=Y1337Y;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=267;ao=5;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C4011T;aa_name=p.Y1337Y;hgvs_nt=NC_045512.2:g.4011C>T;hgvs_aa=YP_009724389.1:p.Tyr1337Tyr;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01838235294117647;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	4456	4456	.	+	.	ID=ID_16;Name=A1397A;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=269;ao=3;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C4191T;aa_name=p.A1397A;hgvs_nt=NC_045512.2:g.4191C>T;hgvs_aa=YP_009724389.1:p.Ala1397Ala;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.011029411764705883;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	5301	5301	.	+	.	ID=ID_17;Name=A1679V;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=261;ao=11;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C5036T;aa_name=p.A1679V;hgvs_nt=NC_045512.2:g.5036C>T;hgvs_aa=YP_009724389.1:p.Ala1679Val;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.04044117647058824;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	5716	5716	.	+	.	ID=ID_18;Name=K1817N;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=141;ao=131;dp=272;sample_size=280;Reference_seq=G;Variant_seq=T;nt_name=g.G5451T;aa_name=p.K1817N;hgvs_nt=NC_045512.2:g.5451G>T;hgvs_aa=YP_009724389.1:p.Lys1817Asn;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.48161764705882354;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	5724	5724	.	+	.	ID=ID_19;Name=T1820I;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=267;ao=5;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C5459T;aa_name=p.T1820I;hgvs_nt=NC_045512.2:g.5459C>T;hgvs_aa=YP_009724389.1:p.Thr1820Ile;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01838235294117647;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	5891	5891	.	+	.	ID=ID_20;Name=T1876A;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=266;ao=5;dp=271;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A5626G;aa_name=p.T1876A;hgvs_nt=NC_045512.2:g.5626A>G;hgvs_aa=YP_009724389.1:p.Thr1876Ala;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01845018450184502;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	6026	6026	.	+	.	ID=ID_21;Name=P1921S;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=266;ao=3;dp=269;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C5761T;aa_name=p.P1921S;hgvs_nt=NC_045512.2:g.5761C>T;hgvs_aa=YP_009724389.1:p.Pro1921Ser;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.011152416356877323;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	6101	6101	.	+	.	ID=ID_22;Name=G1946S;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=255;ao=15;dp=270;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G5836A;aa_name=p.G1946S;hgvs_nt=NC_045512.2:g.5836G>A;hgvs_aa=YP_009724389.1:p.Gly1946Ser;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05555555555555555;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	6310	6310	.	+	.	ID=ID_23;Name=S2015S;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=268;ao=4;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C6045T;aa_name=p.S2015S;hgvs_nt=NC_045512.2:g.6045C>T;hgvs_aa=YP_009724389.1:p.Ser2015Ser;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.014705882352941176;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	6379	6379	.	+	.	ID=ID_24;Name=N2038N;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=264;ao=7;dp=271;sample_size=280;Reference_seq=T;Variant_seq=C;nt_name=g.T6114C;aa_name=p.N2038N;hgvs_nt=NC_045512.2:g.6114T>C;hgvs_aa=YP_009724389.1:p.Asn2038Asn;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.025830258302583026;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	7201	7201	.	+	.	ID=ID_25;Name=S2312S;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=256;ao=15;dp=271;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A6936G;aa_name=p.S2312S;hgvs_nt=NC_045512.2:g.6936A>G;hgvs_aa=YP_009724389.1:p.Ser2312Ser;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.055350553505535055;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	7711	7711	.	+	.	ID=ID_26;Name=N2482N;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=270;ao=2;dp=272;sample_size=280;Reference_seq=T;Variant_seq=C;nt_name=g.T7446C;aa_name=p.N2482N;hgvs_nt=NC_045512.2:g.7446T>C;hgvs_aa=YP_009724389.1:p.Asn2482Asn;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007352941176470588;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	8809	8809	.	+	.	ID=ID_27;Name=D2848D;alias=D85D;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=257;ao=14;dp=271;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C8544T;aa_name=p.D2848D;hgvs_nt=NC_045512.2:g.8544C>T;hgvs_aa=YP_009724389.1:p.Asp2848Asp;hgvs_alias=YP_009724389.1:Asp85Asp;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05166051660516605;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	9207	9207	.	+	.	ID=ID_28;Name=S2981F;alias=S218F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=214;ao=58;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C8942T;aa_name=p.S2981F;hgvs_nt=NC_045512.2:g.8942C>T;hgvs_aa=YP_009724389.1:p.Ser2981Phe;hgvs_alias=YP_009724389.1:Ser218Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.21323529411764705;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	9220	9220	.	+	.	ID=ID_29;Name=R2985R;alias=R222R;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=261;ao=11;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G8955A;aa_name=p.R2985R;hgvs_nt=NC_045512.2:g.8955G>A;hgvs_aa=YP_009724389.1:p.Arg2985Arg;hgvs_alias=YP_009724389.1:Arg222Arg;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.04044117647058824;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	9430	9430	.	+	.	ID=ID_30;Name=I3055I;alias=I292I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=261;ao=11;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C9165T;aa_name=p.I3055I;hgvs_nt=NC_045512.2:g.9165C>T;hgvs_aa=YP_009724389.1:p.Ile3055Ile;hgvs_alias=YP_009724389.1:Ile292Ile;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.04044117647058824;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	9805	9805	.	+	.	ID=ID_31;Name=L3180L;alias=L417L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=269;ao=3;dp=272;sample_size=280;Reference_seq=G;Variant_seq=T;nt_name=g.G9540T;aa_name=p.L3180L;hgvs_nt=NC_045512.2:g.9540G>T;hgvs_aa=YP_009724389.1:p.Leu3180Leu;hgvs_alias=YP_009724389.1:Leu417Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.011029411764705883;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	9867	9867	.	+	.	ID=ID_32;Name=L3201P;alias=L438P;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=T;Variant_seq=C;nt_name=g.T9602C;aa_name=p.L3201P;hgvs_nt=NC_045512.2:g.9602T>C;hgvs_aa=YP_009724389.1:p.Leu3201Pro;hgvs_alias=YP_009724389.1:Leu438Pro;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	10252	10252	.	+	.	ID=ID_33;Name=F3329F;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3264..3569;ro=269;ao=3;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C9987T;aa_name=p.F3329F;hgvs_nt=NC_045512.2:g.9987C>T;hgvs_aa=YP_009724389.1:p.Phe3329Phe;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.011029411764705883;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	10255	10255	.	+	.	ID=ID_34;Name=L3330F;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3264..3569;ro=270;ao=2;dp=272;sample_size=280;Reference_seq=G;Variant_seq=T;nt_name=g.G9990T;aa_name=p.L3330F;hgvs_nt=NC_045512.2:g.9990G>T;hgvs_aa=YP_009724389.1:p.Leu3330Phe;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007352941176470588;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	10277	10277	.	+	.	ID=ID_35;Name=L3338F;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3264..3569;ro=141;ao=131;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C10012T;aa_name=p.L3338F;hgvs_nt=NC_045512.2:g.10012C>T;hgvs_aa=YP_009724389.1:p.Leu3338Phe;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.48161764705882354;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	10376	10376	.	+	.	ID=ID_36;Name=P3371S;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3264..3569;ro=267;ao=5;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C10111T;aa_name=p.P3371S;hgvs_nt=NC_045512.2:g.10111C>T;hgvs_aa=YP_009724389.1:p.Pro3371Ser;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01838235294117647;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	10722	10722	.	+	.	ID=ID_37;Name=F3486S;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3264..3569;ro=267;ao=5;dp=272;sample_size=280;Reference_seq=T;Variant_seq=C;nt_name=g.T10457C;aa_name=p.F3486S;hgvs_nt=NC_045512.2:g.10457T>C;hgvs_aa=YP_009724389.1:p.Phe3486Ser;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01838235294117647;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	10775	10775	.	+	.	ID=ID_38;Name=P3504S;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3264..3569;ro=269;ao=3;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C10510T;aa_name=p.P3504S;hgvs_nt=NC_045512.2:g.10510C>T;hgvs_aa=YP_009724389.1:p.Pro3504Ser;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.011029411764705883;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	11068	11068	.	+	.	ID=ID_39;Name=S3601S;alias=S32S;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=268;ao=4;dp=272;sample_size=280;Reference_seq=T;Variant_seq=G;nt_name=g.T10803G;aa_name=p.S3601S;hgvs_nt=NC_045512.2:g.10803T>G;hgvs_aa=YP_009724389.1:p.Ser3601Ser;hgvs_alias=YP_009724389.1:Ser32Ser;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.014705882352941176;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	11083	11083	.	+	.	ID=ID_40;Name=L3606F;alias=L37F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=269;ao=3;dp=272;sample_size=280;Reference_seq=G;Variant_seq=T;nt_name=g.G10818T;aa_name=p.L3606F;hgvs_nt=NC_045512.2:g.10818G>T;hgvs_aa=YP_009724389.1:p.Leu3606Phe;hgvs_alias=YP_009724389.1:Leu37Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.011029411764705883;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	del	11287	11287	.	+	.	ID=ID_41;Name=S3675del;alias=S106_F108del;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=GTCTGGTTTT;Variant_seq=G;nt_name=g.11023_11031delTCTGGTTTT;aa_name=p.S3675_F3677del;hgvs_nt=NC_045512.2:g.11023_11031del;hgvs_aa=YP_009724389.1:p.Ser3675_Phe3677del;hgvs_alias=YP_009724389.1:Ser106_Phe108del;vcf_gene=ORF1ab;mutation_type=;viral_lineage=B.1.526;multi_aa_name=S3675_F3677del;multiaa_comb_mutation=3676del,F3677del;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	del	11287	11287	.	+	.	ID=ID_41;Name=3676del;alias=S106_F108del;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=GTCTGGTTTT;Variant_seq=G;nt_name=g.11023_11031delTCTGGTTTT;aa_name=p.S3675_F3677del;hgvs_nt=NC_045512.2:g.11023_11031del;hgvs_aa=YP_009724389.1:p.Ser3675_Phe3677del;hgvs_alias=YP_009724389.1:Ser106_Phe108del;vcf_gene=ORF1ab;mutation_type=;viral_lineage=B.1.526;multi_aa_name=S3675_F3677del;multiaa_comb_mutation=S3675del,F3677del;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	del	11287	11287	.	+	.	ID=ID_41;Name=F3677del;alias=S106_F108del;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=GTCTGGTTTT;Variant_seq=G;nt_name=g.11023_11031delTCTGGTTTT;aa_name=p.S3675_F3677del;hgvs_nt=NC_045512.2:g.11023_11031del;hgvs_aa=YP_009724389.1:p.Ser3675_Phe3677del;hgvs_alias=YP_009724389.1:Ser106_Phe108del;vcf_gene=ORF1ab;mutation_type=;viral_lineage=B.1.526;multi_aa_name=S3675_F3677del;multiaa_comb_mutation=S3675del,3676del;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	11399	11399	.	+	.	ID=ID_42;Name=M3712V;alias=M143V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=269;ao=3;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A11134G;aa_name=p.M3712V;hgvs_nt=NC_045512.2:g.11134A>G;hgvs_aa=YP_009724389.1:p.Met3712Val;hgvs_alias=YP_009724389.1:Met143Val;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.011029411764705883;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	11601	11601	.	+	.	ID=ID_43;Name=I3779T;alias=I210T;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=266;ao=6;dp=272;sample_size=280;Reference_seq=T;Variant_seq=C;nt_name=g.T11336C;aa_name=p.I3779T;hgvs_nt=NC_045512.2:g.11336T>C;hgvs_aa=YP_009724389.1:p.Ile3779Thr;hgvs_alias=YP_009724389.1:Ile210Thr;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.022058823529411766;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	11653	11653	.	+	.	ID=ID_44;Name=L3796L;alias=L227L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=270;ao=2;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C11388T;aa_name=p.L3796L;hgvs_nt=NC_045512.2:g.11388C>T;hgvs_aa=YP_009724389.1:p.Leu3796Leu;hgvs_alias=YP_009724389.1:Leu227Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007352941176470588;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	12132	12132	.	+	.	ID=ID_45;Name=A3956V;alias=A14V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp8;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3943..4140;ro=269;ao=3;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C11867T;aa_name=p.A3956V;hgvs_nt=NC_045512.2:g.11867C>T;hgvs_aa=YP_009724389.1:p.Ala3956Val;hgvs_alias=YP_009724389.1:Ala14Val;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.011029411764705883;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	12312	12312	.	+	.	ID=ID_46;Name=A4016V;alias=A74V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp8;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3943..4140;ro=270;ao=2;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C12047T;aa_name=p.A4016V;hgvs_nt=NC_045512.2:g.12047C>T;hgvs_aa=YP_009724389.1:p.Ala4016Val;hgvs_alias=YP_009724389.1:Ala74Val;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007352941176470588;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	12781	12781	.	+	.	ID=ID_47;Name=Y4172Y;alias=Y32Y;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp9;mat_pep_desc=ssRNA-binding protein%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:4141..4253;ro=268;ao=4;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C12516T;aa_name=p.Y4172Y;hgvs_nt=NC_045512.2:g.12516C>T;hgvs_aa=YP_009724389.1:p.Tyr4172Tyr;hgvs_alias=YP_009724389.1:Tyr32Tyr;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.014705882352941176;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	12960	12960	.	+	.	ID=ID_48;Name=K4232R;alias=K92R;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp9;mat_pep_desc=ssRNA-binding protein%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:4141..4253;ro=264;ao=8;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A12695G;aa_name=p.K4232R;hgvs_nt=NC_045512.2:g.12695A>G;hgvs_aa=YP_009724389.1:p.Lys4232Arg;hgvs_alias=YP_009724389.1:Lys92Arg;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.029411764705882353;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	12970	12970	.	+	.	ID=ID_49;Name=N4235N;alias=N95N;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp9;mat_pep_desc=ssRNA-binding protein%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:4141..4253;ro=270;ao=2;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C12705T;aa_name=p.N4235N;hgvs_nt=NC_045512.2:g.12705C>T;hgvs_aa=YP_009724389.1:p.Asn4235Asn;hgvs_alias=YP_009724389.1:Asn95Asn;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007352941176470588;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	13176	13176	.	+	.	ID=ID_50;Name=T4304I;alias=T51I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp10;mat_pep_desc=nsp10_CysHis%3B formerly known as growth-factor-like protein (GFL)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:4254..4392;ro=261;ao=11;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C12911T;aa_name=p.T4304I;hgvs_nt=NC_045512.2:g.12911C>T;hgvs_aa=YP_009724389.1:p.Thr4304Ile;hgvs_alias=YP_009724389.1:Thr51Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.04044117647058824;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	13625	13625	.	+	.	ID=ID_51;Name=D4454G;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=139;ao=131;dp=270;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A13361G;aa_name=p.D4454G;hgvs_nt=NC_045512.2:g.13361A>G;hgvs_aa=YP_009724389.1:p.Asp4454Gly;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.48518518518518516;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	13785	13785	.	+	.	ID=ID_52;Name=S4507S;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=141;ao=131;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A13521G;aa_name=p.S4507S;hgvs_nt=NC_045512.2:g.13521A>G;hgvs_aa=YP_009724389.1:p.Ser4507Ser;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.48161764705882354;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	13977	13977	.	+	.	ID=ID_53;Name=G4571G;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=269;ao=3;dp=272;sample_size=280;Reference_seq=T;Variant_seq=C;nt_name=g.T13713C;aa_name=p.G4571G;hgvs_nt=NC_045512.2:g.13713T>C;hgvs_aa=YP_009724389.1:p.Gly4571Gly;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.011029411764705883;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	14184	14184	.	+	.	ID=ID_54;Name=T4640T;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=270;ao=2;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C13920T;aa_name=p.T4640T;hgvs_nt=NC_045512.2:g.13920C>T;hgvs_aa=YP_009724389.1:p.Thr4640Thr;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007352941176470588;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	14210	14210	.	+	.	ID=ID_55;Name=V4649A;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=270;ao=2;dp=272;sample_size=280;Reference_seq=T;Variant_seq=C;nt_name=g.T13946C;aa_name=p.V4649A;hgvs_nt=NC_045512.2:g.13946T>C;hgvs_aa=YP_009724389.1:p.Val4649Ala;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007352941176470588;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	14408	14408	.	+	.	ID=ID_56;Name=P4715L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C14144T;aa_name=p.P4715L;hgvs_nt=NC_045512.2:g.14144C>T;hgvs_aa=YP_009724389.1:p.Pro4715Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	14457	14457	.	+	.	ID=ID_57;Name=P4731P;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=252;ao=20;dp=272;sample_size=280;Reference_seq=A;Variant_seq=T;nt_name=g.A14193T;aa_name=p.P4731P;hgvs_nt=NC_045512.2:g.14193A>T;hgvs_aa=YP_009724389.1:p.Pro4731Pro;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.07352941176470588;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	14616	14616	.	+	.	ID=ID_58;Name=R4784R;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=270;ao=2;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C14352T;aa_name=p.R4784R;hgvs_nt=NC_045512.2:g.14352C>T;hgvs_aa=YP_009724389.1:p.Arg4784Arg;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007352941176470588;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	15720	15720	.	+	.	ID=ID_59;Name=D5152D;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=209;ao=60;dp=269;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C15456T;aa_name=p.D5152D;hgvs_nt=NC_045512.2:g.15456C>T;hgvs_aa=YP_009724389.1:p.Asp5152Asp;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.22304832713754646;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	15952	15952	.	+	.	ID=ID_60;Name=L5230L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=268;ao=2;dp=270;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C15688T;aa_name=p.L5230L;hgvs_nt=NC_045512.2:g.15688C>T;hgvs_aa=YP_009724389.1:p.Leu5230Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007407407407407408;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	16308	16308	.	+	.	ID=ID_61;Name=F5348F;alias=F24F;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=268;ao=2;dp=270;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C16044T;aa_name=p.F5348F;hgvs_nt=NC_045512.2:g.16044C>T;hgvs_aa=YP_009724389.1:p.Phe5348Phe;hgvs_alias=YP_009724389.1:Phe24Phe;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007407407407407408;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	16500	16500	.	+	.	ID=ID_62;Name=Q5412H;alias=Q88H;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=0;ao=270;dp=270;sample_size=280;Reference_seq=A;Variant_seq=C;nt_name=g.A16236C;aa_name=p.Q5412H;hgvs_nt=NC_045512.2:g.16236A>C;hgvs_aa=YP_009724389.1:p.Gln5412His;hgvs_alias=YP_009724389.1:Gln88His;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	16898	16898	.	+	.	ID=ID_63;Name=V5545G;alias=V221G;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=238;ao=34;dp=272;sample_size=280;Reference_seq=T;Variant_seq=G;nt_name=g.T16634G;aa_name=p.V5545G;hgvs_nt=NC_045512.2:g.16634T>G;hgvs_aa=YP_009724389.1:p.Val5545Gly;hgvs_alias=YP_009724389.1:Val221Gly;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.125;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	17004	17004	.	+	.	ID=ID_64;Name=L5580L;alias=L256L;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=262;ao=10;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C16740T;aa_name=p.L5580L;hgvs_nt=NC_045512.2:g.16740C>T;hgvs_aa=YP_009724389.1:p.Leu5580Leu;hgvs_alias=YP_009724389.1:Leu256Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03676470588235294;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	17597	17597	.	+	.	ID=ID_65;Name=A5778V;alias=A454V;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=270;ao=2;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C17333T;aa_name=p.A5778V;hgvs_nt=NC_045512.2:g.17333C>T;hgvs_aa=YP_009724389.1:p.Ala5778Val;hgvs_alias=YP_009724389.1:Ala454Val;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007352941176470588;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	17865	17865	.	+	.	ID=ID_66;Name=Y5867Y;alias=Y543Y;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=266;ao=4;dp=270;sample_size=280;Reference_seq=T;Variant_seq=C;nt_name=g.T17601C;aa_name=p.Y5867Y;hgvs_nt=NC_045512.2:g.17601T>C;hgvs_aa=YP_009724389.1:p.Tyr5867Tyr;hgvs_alias=YP_009724389.1:Tyr543Tyr;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.014814814814814815;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	18429	18429	.	+	.	ID=ID_67;Name=N6055N;alias=N130N;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=269;ao=2;dp=271;sample_size=280;Reference_seq=T;Variant_seq=C;nt_name=g.T18165C;aa_name=p.N6055N;hgvs_nt=NC_045512.2:g.18165T>C;hgvs_aa=YP_009724389.1:p.Asn6055Asn;hgvs_alias=YP_009724389.1:Asn130Asn;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007380073800738007;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	19071	19071	.	+	.	ID=ID_68;Name=A6269A;alias=A344A;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=270;ao=2;dp=272;sample_size=280;Reference_seq=T;Variant_seq=C;nt_name=g.T18807C;aa_name=p.A6269A;hgvs_nt=NC_045512.2:g.18807T>C;hgvs_aa=YP_009724389.1:p.Ala6269Ala;hgvs_alias=YP_009724389.1:Ala344Ala;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007352941176470588;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	19086	19086	.	+	.	ID=ID_69;Name=K6274N;alias=K349N;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=258;ao=14;dp=272;sample_size=280;Reference_seq=G;Variant_seq=T;nt_name=g.G18822T;aa_name=p.K6274N;hgvs_nt=NC_045512.2:g.18822G>T;hgvs_aa=YP_009724389.1:p.Lys6274Asn;hgvs_alias=YP_009724389.1:Lys349Asn;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.051470588235294115;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	20233	20233	.	+	.	ID=ID_70;Name=P6657S;alias=P205S;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp15;mat_pep_desc=nsp15-A1 and nsp15B-NendoU%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6453..6798;ro=264;ao=5;dp=269;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C19969T;aa_name=p.P6657S;hgvs_nt=NC_045512.2:g.19969C>T;hgvs_aa=YP_009724389.1:p.Pro6657Ser;hgvs_alias=YP_009724389.1:Pro205Ser;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01858736059479554;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	20262	20262	.	+	.	ID=ID_71;Name=L6666L;alias=L214L;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp15;mat_pep_desc=nsp15-A1 and nsp15B-NendoU%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6453..6798;ro=0;ao=270;dp=270;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A19998G;aa_name=p.L6666L;hgvs_nt=NC_045512.2:g.19998A>G;hgvs_aa=YP_009724389.1:p.Leu6666Leu;hgvs_alias=YP_009724389.1:Leu214Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	20437	20437	.	+	.	ID=ID_72;Name=S6725G;alias=S273G;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp15;mat_pep_desc=nsp15-A1 and nsp15B-NendoU%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6453..6798;ro=237;ao=31;dp=268;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A20173G;aa_name=p.S6725G;hgvs_nt=NC_045512.2:g.20173A>G;hgvs_aa=YP_009724389.1:p.Ser6725Gly;hgvs_alias=YP_009724389.1:Ser273Gly;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.11567164179104478;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	20592	20592	.	+	.	ID=ID_73;Name=Y6776Y;alias=Y324Y;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp15;mat_pep_desc=nsp15-A1 and nsp15B-NendoU%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6453..6798;ro=263;ao=3;dp=266;sample_size=280;Reference_seq=T;Variant_seq=C;nt_name=g.T20328C;aa_name=p.Y6776Y;hgvs_nt=NC_045512.2:g.20328T>C;hgvs_aa=YP_009724389.1:p.Tyr6776Tyr;hgvs_alias=YP_009724389.1:Tyr324Tyr;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.011278195488721804;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	20703	20703	.	+	.	ID=ID_74;Name=Y6813Y;alias=Y15Y;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp16;mat_pep_desc=nsp16_OMT%3B 2'-o-MT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6799..7096;ro=261;ao=10;dp=271;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C20439T;aa_name=p.Y6813Y;hgvs_nt=NC_045512.2:g.20439C>T;hgvs_aa=YP_009724389.1:p.Tyr6813Tyr;hgvs_alias=YP_009724389.1:Tyr15Tyr;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03690036900369004;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21058	21058	.	+	.	ID=ID_75;Name=P6932S;alias=P134S;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp16;mat_pep_desc=nsp16_OMT%3B 2'-o-MT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6799..7096;ro=267;ao=4;dp=271;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C20794T;aa_name=p.P6932S;hgvs_nt=NC_045512.2:g.20794C>T;hgvs_aa=YP_009724389.1:p.Pro6932Ser;hgvs_alias=YP_009724389.1:Pro134Ser;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.014760147601476014;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21077	21077	.	+	.	ID=ID_76;Name=T6938I;alias=T140I;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp16;mat_pep_desc=nsp16_OMT%3B 2'-o-MT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6799..7096;ro=269;ao=2;dp=271;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C20813T;aa_name=p.T6938I;hgvs_nt=NC_045512.2:g.20813C>T;hgvs_aa=YP_009724389.1:p.Thr6938Ile;hgvs_alias=YP_009724389.1:Thr140Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007380073800738007;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21575	21575	.	+	.	ID=ID_77;Name=L5F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=270;dp=270;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C13T;aa_name=p.L5F;hgvs_nt=NC_045512.2:g.13C>T;hgvs_aa=YP_009724390.1:p.Leu5Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.1x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21575	21575	.	+	.	ID=ID_78;Name=L5F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=270;dp=270;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C13T;aa_name=p.L5F;hgvs_nt=NC_045512.2:g.13C>T;hgvs_aa=YP_009724390.1:p.Leu5Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,T95I,D253G,E484K,A701V;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.526) showed a 1.78x increase  in binding (KD) relative to D614G, even though each variant independently decreases binding.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21575	21575	.	+	.	"ID=ID_79;Name=L5F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=270;dp=270;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C13T;aa_name=p.L5F;hgvs_nt=NC_045512.2:g.13C>T;hgvs_aa=YP_009724390.1:p.Leu5Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1;citation=Zhou et al. (2021);comb_mutation=T95I,D253G,S477N,D614G,A701V;function_description=Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed no significant  change in IC50 serum dilution concentration for 6 convalescent sera.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	21575	21575	.	+	.	"ID=ID_78;Name=L5F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=270;dp=270;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C13T;aa_name=p.L5F;hgvs_nt=NC_045512.2:g.13C>T;hgvs_aa=YP_009724390.1:p.Leu5Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1;citation=Zhou et al. (2021);comb_mutation=T95I,D253G,E484K,D614G,A701V;function_description=Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.8x reduction in  IC50 serum dilution concentration for 6 convalescent sera.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	21575	21575	.	+	.	ID=ID_77;Name=L5F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=270;dp=270;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C13T;aa_name=p.L5F;hgvs_nt=NC_045512.2:g.13C>T;hgvs_aa=YP_009724390.1:p.Leu5Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21575	21575	.	+	.	ID=ID_78;Name=L5F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=270;dp=270;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C13T;aa_name=p.L5F;hgvs_nt=NC_045512.2:g.13C>T;hgvs_aa=YP_009724390.1:p.Leu5Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,T95I,D253G,E484K,A701V;function_description=This variant combination (representing lineage B.1.526) showed a 1.02x increase in Spike binding (relative  to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21575	21575	.	+	.	"ID=ID_79;Name=L5F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=270;dp=270;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C13T;aa_name=p.L5F;hgvs_nt=NC_045512.2:g.13C>T;hgvs_aa=YP_009724390.1:p.Leu5Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1;citation=Zhou et al. (2021);comb_mutation=T95I,D253G,S477N,D614G,A701V;function_description=Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed no significant change in IC50 serum dilution concentration for sera from BNT162b2 (Pzifer) or mRNA1273 (Moderna) vacinees collected 28 days following booster dose.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	21575	21575	.	+	.	ID=ID_79;Name=L5F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=270;dp=270;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C13T;aa_name=p.L5F;hgvs_nt=NC_045512.2:g.13C>T;hgvs_aa=YP_009724390.1:p.Leu5Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation=T95I,D253G,S477N,D614G,A701V;function_description=Neutralization efficiency (ID50) against B.1.526 reduced 2.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21575	21575	.	+	.	"ID=ID_78;Name=L5F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=270;dp=270;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C13T;aa_name=p.L5F;hgvs_nt=NC_045512.2:g.13C>T;hgvs_aa=YP_009724390.1:p.Leu5Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1;citation=Zhou et al. (2021);comb_mutation=T95I,D253G,E484K,D614G,A701V;function_description=Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.6x reduction in both IC50 serum dilution concentration for sera from 5 BNT162b2 (Pzifer) or 3 mRNA1273 (Moderna) vacinees collected 28 days following booster dose.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	21575	21575	.	+	.	ID=ID_78;Name=L5F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=270;dp=270;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C13T;aa_name=p.L5F;hgvs_nt=NC_045512.2:g.13C>T;hgvs_aa=YP_009724390.1:p.Leu5Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1;citation=Pegu et al (2021);comb_mutation=T95I,D253G,E484K,D614G,A701V;function_description=Detectable antibodies against B.1.526+E484K at various time points using pseudotyped lentivirus neutralization in Moderna vaccinee cohort: Day 43 100%, Day 209 88%.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21575	21575	.	+	.	ID=ID_78;Name=L5F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=270;dp=270;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C13T;aa_name=p.L5F;hgvs_nt=NC_045512.2:g.13C>T;hgvs_aa=YP_009724390.1:p.Leu5Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=T95I,D253G,E484K,D614G,A701V;function_description=2.3x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees);heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21575	21575	.	+	.	ID=ID_77;Name=L5F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=270;dp=270;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C13T;aa_name=p.L5F;hgvs_nt=NC_045512.2:g.13C>T;hgvs_aa=YP_009724390.1:p.Leu5Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.23x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21575	21575	.	+	.	ID=ID_78;Name=L5F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=270;dp=270;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C13T;aa_name=p.L5F;hgvs_nt=NC_045512.2:g.13C>T;hgvs_aa=YP_009724390.1:p.Leu5Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,T95I,D253G,E484K,A701V;function_description=This variant combination (representing lineage B.1.526) showed a 1.34x increase in Spike binding (relative  to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21595	21595	.	+	.	ID=ID_80;Name=V11V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=263;ao=9;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C33T;aa_name=p.V11V;hgvs_nt=NC_045512.2:g.33C>T;hgvs_aa=YP_009724390.1:p.Val11Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03308823529411765;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21785	21785	.	+	.	ID=ID_81;Name=G75S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=140;ao=131;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G223A;aa_name=p.G75S;hgvs_nt=NC_045512.2:g.223G>A;hgvs_aa=YP_009724390.1:p.Gly75Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.48161764705882354;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21846	21846	.	+	.	ID=ID_82;Name=T95I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C284T;aa_name=p.T95I;hgvs_nt=NC_045512.2:g.284C>T;hgvs_aa=YP_009724390.1:p.Thr95Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.33x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21846	21846	.	+	.	ID=ID_78;Name=T95I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C284T;aa_name=p.T95I;hgvs_nt=NC_045512.2:g.284C>T;hgvs_aa=YP_009724390.1:p.Thr95Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,L5F,D253G,E484K,A701V;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.526) showed a 1.78x increase  in binding (KD) relative to D614G, even though each variant independently decreases binding.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21846	21846	.	+	.	ID=ID_83;Name=T95I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C284T;aa_name=p.T95I;hgvs_nt=NC_045512.2:g.284C>T;hgvs_aa=YP_009724390.1:p.Thr95Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=outcome hazard ratio;source=https://www.medrxiv.org/content/10.1101/2021.08.04.21261596v1;citation=Yang et al. (2021);comb_mutation=D253G,D614G;function_description=B.1.526 (Iota) substantially increased IFR in older adults: by 46% (95% CI: 7.4  84%) among 45-64 year-olds,  82% (95% CI: 20  140%) among 65-74 year-olds, and 62% (95% CI: 45  80%) among 75+ during Nov 2020  Apr 2021,  compared to baseline IFR estimated for preexisting variants. [minimum clade defining mutations listed];heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21846	21846	.	+	.	"ID=ID_79;Name=T95I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C284T;aa_name=p.T95I;hgvs_nt=NC_045512.2:g.284C>T;hgvs_aa=YP_009724390.1:p.Thr95Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1;citation=Zhou et al. (2021);comb_mutation=L5F,D253G,S477N,D614G,A701V;function_description=Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed no significant  change in IC50 serum dilution concentration for 6 convalescent sera.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	21846	21846	.	+	.	"ID=ID_78;Name=T95I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C284T;aa_name=p.T95I;hgvs_nt=NC_045512.2:g.284C>T;hgvs_aa=YP_009724390.1:p.Thr95Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1;citation=Zhou et al. (2021);comb_mutation=L5F,D253G,E484K,D614G,A701V;function_description=Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.8x reduction in  IC50 serum dilution concentration for 6 convalescent sera.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	21846	21846	.	+	.	ID=ID_82;Name=T95I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C284T;aa_name=p.T95I;hgvs_nt=NC_045512.2:g.284C>T;hgvs_aa=YP_009724390.1:p.Thr95Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21846	21846	.	+	.	ID=ID_78;Name=T95I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C284T;aa_name=p.T95I;hgvs_nt=NC_045512.2:g.284C>T;hgvs_aa=YP_009724390.1:p.Thr95Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,L5F,D253G,E484K,A701V;function_description=This variant combination (representing lineage B.1.526) showed a 1.02x increase in Spike binding (relative  to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21846	21846	.	+	.	"ID=ID_79;Name=T95I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C284T;aa_name=p.T95I;hgvs_nt=NC_045512.2:g.284C>T;hgvs_aa=YP_009724390.1:p.Thr95Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1;citation=Zhou et al. (2021);comb_mutation=L5F,D253G,S477N,D614G,A701V;function_description=Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed no significant change in IC50 serum dilution concentration for sera from BNT162b2 (Pzifer) or mRNA1273 (Moderna) vacinees collected 28 days following booster dose.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	21846	21846	.	+	.	ID=ID_79;Name=T95I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C284T;aa_name=p.T95I;hgvs_nt=NC_045512.2:g.284C>T;hgvs_aa=YP_009724390.1:p.Thr95Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation=L5F,D253G,S477N,D614G,A701V;function_description=Neutralization efficiency (ID50) against B.1.526 reduced 2.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21846	21846	.	+	.	"ID=ID_78;Name=T95I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C284T;aa_name=p.T95I;hgvs_nt=NC_045512.2:g.284C>T;hgvs_aa=YP_009724390.1:p.Thr95Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1;citation=Zhou et al. (2021);comb_mutation=L5F,D253G,E484K,D614G,A701V;function_description=Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.6x reduction in both IC50 serum dilution concentration for sera from 5 BNT162b2 (Pzifer) or 3 mRNA1273 (Moderna) vacinees collected 28 days following booster dose.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	21846	21846	.	+	.	ID=ID_78;Name=T95I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C284T;aa_name=p.T95I;hgvs_nt=NC_045512.2:g.284C>T;hgvs_aa=YP_009724390.1:p.Thr95Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1;citation=Pegu et al (2021);comb_mutation=L5F,D253G,E484K,D614G,A701V;function_description=Detectable antibodies against B.1.526+E484K at various time points using pseudotyped lentivirus neutralization in Moderna vaccinee cohort: Day 43 100%, Day 209 88%.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21846	21846	.	+	.	ID=ID_78;Name=T95I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C284T;aa_name=p.T95I;hgvs_nt=NC_045512.2:g.284C>T;hgvs_aa=YP_009724390.1:p.Thr95Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L5F,D253G,E484K,D614G,A701V;function_description=2.3x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees);heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21846	21846	.	+	.	ID=ID_82;Name=T95I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C284T;aa_name=p.T95I;hgvs_nt=NC_045512.2:g.284C>T;hgvs_aa=YP_009724390.1:p.Thr95Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.02x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21846	21846	.	+	.	ID=ID_78;Name=T95I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C284T;aa_name=p.T95I;hgvs_nt=NC_045512.2:g.284C>T;hgvs_aa=YP_009724390.1:p.Thr95Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,L5F,D253G,E484K,A701V;function_description=This variant combination (representing lineage B.1.526) showed a 1.34x increase in Spike binding (relative  to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	21941	21941	.	+	.	ID=ID_84;Name=V127F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=258;ao=14;dp=272;sample_size=280;Reference_seq=G;Variant_seq=T;nt_name=g.G379T;aa_name=p.V127F;hgvs_nt=NC_045512.2:g.379G>T;hgvs_aa=YP_009724390.1:p.Val127Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.051470588235294115;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22320	22320	.	+	.	"ID=ID_85;Name=D253G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=267;dp=267;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A758G;aa_name=p.D253G;hgvs_nt=NC_045512.2:g.758A>G;hgvs_aa=YP_009724390.1:p.Asp253Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.14.426475;citation=McCallum et al. (2021);comb_mutation=;function_description=Massive reduction in S2L28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i"", but no effect on other mAbs within that supersite;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	22320	22320	.	+	.	ID=ID_86;Name=D253G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=267;dp=267;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A758G;aa_name=p.D253G;hgvs_nt=NC_045512.2:g.758A>G;hgvs_aa=YP_009724390.1:p.Asp253Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.08x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22320	22320	.	+	.	ID=ID_78;Name=D253G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=267;dp=267;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A758G;aa_name=p.D253G;hgvs_nt=NC_045512.2:g.758A>G;hgvs_aa=YP_009724390.1:p.Asp253Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,L5F,T95I,E484K,A701V;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.526) showed a 1.78x increase  in binding (KD) relative to D614G, even though each variant independently decreases binding.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22320	22320	.	+	.	ID=ID_83;Name=D253G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=267;dp=267;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A758G;aa_name=p.D253G;hgvs_nt=NC_045512.2:g.758A>G;hgvs_aa=YP_009724390.1:p.Asp253Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=outcome hazard ratio;source=https://www.medrxiv.org/content/10.1101/2021.08.04.21261596v1;citation=Yang et al. (2021);comb_mutation=T95I,D614G;function_description=B.1.526 (Iota) substantially increased IFR in older adults: by 46% (95% CI: 7.4  84%) among 45-64 year-olds,  82% (95% CI: 20  140%) among 65-74 year-olds, and 62% (95% CI: 45  80%) among 75+ during Nov 2020  Apr 2021,  compared to baseline IFR estimated for preexisting variants. [minimum clade defining mutations listed];heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22320	22320	.	+	.	"ID=ID_79;Name=D253G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=267;dp=267;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A758G;aa_name=p.D253G;hgvs_nt=NC_045512.2:g.758A>G;hgvs_aa=YP_009724390.1:p.Asp253Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1;citation=Zhou et al. (2021);comb_mutation=L5F,T95I,S477N,D614G,A701V;function_description=Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed no significant  change in IC50 serum dilution concentration for 6 convalescent sera.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	22320	22320	.	+	.	"ID=ID_78;Name=D253G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=267;dp=267;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A758G;aa_name=p.D253G;hgvs_nt=NC_045512.2:g.758A>G;hgvs_aa=YP_009724390.1:p.Asp253Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1;citation=Zhou et al. (2021);comb_mutation=L5F,T95I,E484K,D614G,A701V;function_description=Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.8x reduction in  IC50 serum dilution concentration for 6 convalescent sera.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	22320	22320	.	+	.	ID=ID_86;Name=D253G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=267;dp=267;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A758G;aa_name=p.D253G;hgvs_nt=NC_045512.2:g.758A>G;hgvs_aa=YP_009724390.1:p.Asp253Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22320	22320	.	+	.	ID=ID_78;Name=D253G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=267;dp=267;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A758G;aa_name=p.D253G;hgvs_nt=NC_045512.2:g.758A>G;hgvs_aa=YP_009724390.1:p.Asp253Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,L5F,T95I,E484K,A701V;function_description=This variant combination (representing lineage B.1.526) showed a 1.02x increase in Spike binding (relative  to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22320	22320	.	+	.	"ID=ID_79;Name=D253G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=267;dp=267;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A758G;aa_name=p.D253G;hgvs_nt=NC_045512.2:g.758A>G;hgvs_aa=YP_009724390.1:p.Asp253Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1;citation=Zhou et al. (2021);comb_mutation=L5F,T95I,S477N,D614G,A701V;function_description=Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed no significant change in IC50 serum dilution concentration for sera from BNT162b2 (Pzifer) or mRNA1273 (Moderna) vacinees collected 28 days following booster dose.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	22320	22320	.	+	.	ID=ID_79;Name=D253G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=267;dp=267;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A758G;aa_name=p.D253G;hgvs_nt=NC_045512.2:g.758A>G;hgvs_aa=YP_009724390.1:p.Asp253Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation=L5F,T95I,S477N,D614G,A701V;function_description=Neutralization efficiency (ID50) against B.1.526 reduced 2.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22320	22320	.	+	.	"ID=ID_78;Name=D253G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=267;dp=267;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A758G;aa_name=p.D253G;hgvs_nt=NC_045512.2:g.758A>G;hgvs_aa=YP_009724390.1:p.Asp253Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1;citation=Zhou et al. (2021);comb_mutation=L5F,T95I,E484K,D614G,A701V;function_description=Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.6x reduction in both IC50 serum dilution concentration for sera from 5 BNT162b2 (Pzifer) or 3 mRNA1273 (Moderna) vacinees collected 28 days following booster dose.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	22320	22320	.	+	.	ID=ID_78;Name=D253G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=267;dp=267;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A758G;aa_name=p.D253G;hgvs_nt=NC_045512.2:g.758A>G;hgvs_aa=YP_009724390.1:p.Asp253Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1;citation=Pegu et al (2021);comb_mutation=L5F,T95I,E484K,D614G,A701V;function_description=Detectable antibodies against B.1.526+E484K at various time points using pseudotyped lentivirus neutralization in Moderna vaccinee cohort: Day 43 100%, Day 209 88%.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22320	22320	.	+	.	ID=ID_78;Name=D253G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=267;dp=267;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A758G;aa_name=p.D253G;hgvs_nt=NC_045512.2:g.758A>G;hgvs_aa=YP_009724390.1:p.Asp253Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L5F,T95I,E484K,D614G,A701V;function_description=2.3x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees);heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22320	22320	.	+	.	ID=ID_85;Name=D253G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=267;dp=267;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A758G;aa_name=p.D253G;hgvs_nt=NC_045512.2:g.758A>G;hgvs_aa=YP_009724390.1:p.Asp253Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2021.01.14.426475;citation=McCallum et al. (2021);comb_mutation=;function_description=Escape mutation against Spike N terminal domain antigenic supersite i mAb S2L28;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22320	22320	.	+	.	ID=ID_86;Name=D253G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=267;dp=267;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A758G;aa_name=p.D253G;hgvs_nt=NC_045512.2:g.758A>G;hgvs_aa=YP_009724390.1:p.Asp253Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=No significant change in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22320	22320	.	+	.	ID=ID_78;Name=D253G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=267;dp=267;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A758G;aa_name=p.D253G;hgvs_nt=NC_045512.2:g.758A>G;hgvs_aa=YP_009724390.1:p.Asp253Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,L5F,T95I,E484K,A701V;function_description=This variant combination (representing lineage B.1.526) showed a 1.34x increase in Spike binding (relative  to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22992	22992	.	+	.	ID=ID_87;Name=S477N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=255;ao=17;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1430A;aa_name=p.S477N;hgvs_nt=NC_045512.2:g.1430G>A;hgvs_aa=YP_009724390.1:p.Ser477Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0625;function_category=symptom prevalence;source=https://doi.org/10.1016/j.ijid.2021.03.068;citation=Fournier et al. (2021);comb_mutation=D614G;function_description=Compared to the clade 20A strains that predominated during phase 1 between March and May 2020, the Marseille-4 variant (characterized  by this mutation plus N:p.M234I:A376T) was associated with a lower frequency of cough, rhinitis, and olfactory and gustatory disorders.  By contrast, hypoxemia was more frequent in patients infected with the Marseille-4 variant.;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22992	22992	.	+	.	ID=ID_88;Name=S477N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=255;ao=17;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1430A;aa_name=p.S477N;hgvs_nt=NC_045512.2:g.1430G>A;hgvs_aa=YP_009724390.1:p.Ser477Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0625;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2021);comb_mutation=;function_description=Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows some resistence across all antibodies tested.;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22992	22992	.	+	.	ID=ID_88;Name=S477N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=255;ao=17;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1430A;aa_name=p.S477N;hgvs_nt=NC_045512.2:g.1430G>A;hgvs_aa=YP_009724390.1:p.Ser477Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0625;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2;citation=Gaebler et al. (2021);comb_mutation=;function_description=Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant.;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22992	22992	.	+	.	ID=ID_88;Name=S477N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=255;ao=17;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1430A;aa_name=p.S477N;hgvs_nt=NC_045512.2:g.1430G>A;hgvs_aa=YP_009724390.1:p.Ser477Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0625;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, ACE2 binding affinity increased 0.06 fold;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22992	22992	.	+	.	ID=ID_88;Name=S477N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=255;ao=17;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1430A;aa_name=p.S477N;hgvs_nt=NC_045512.2:g.1430G>A;hgvs_aa=YP_009724390.1:p.Ser477Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0625;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=;comb_mutation=;function_description=Increased affinity for ACE2: clade in Australia 2020-05-27 onward, clade in Europe 2020-08-08 onward Modelling shows flexible region in Spike RBD with residue S477 having the greatest rotational flexibility.;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22992	22992	.	+	.	ID=ID_88;Name=S477N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=255;ao=17;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1430A;aa_name=p.S477N;hgvs_nt=NC_045512.2:g.1430G>A;hgvs_aa=YP_009724390.1:p.Ser477Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0625;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=;function_description=Among the first selected minor variants in an in vitro evolution experiment for ACE2 binding, with increasing proportion in subsequent rounds.;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22992	22992	.	+	.	ID=ID_87;Name=S477N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=255;ao=17;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1430A;aa_name=p.S477N;hgvs_nt=NC_045512.2:g.1430G>A;hgvs_aa=YP_009724390.1:p.Ser477Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0625;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=D614G;function_description=Lentiviral pseudotyped with the key mutations from 20A.EU2 lineage was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing no significant change in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22992	22992	.	+	.	ID=ID_89;Name=S477N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=255;ao=17;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1430A;aa_name=p.S477N;hgvs_nt=NC_045512.2:g.1430G>A;hgvs_aa=YP_009724390.1:p.Ser477Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0625;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=E484K;function_description=Bamlanivimab (LY-CoV555) lost ~10x binding against this double mutation. Tixagevimab lost ~16x binding against this double mutation.;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22992	22992	.	+	.	ID=ID_87;Name=S477N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=255;ao=17;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1430A;aa_name=p.S477N;hgvs_nt=NC_045512.2:g.1430G>A;hgvs_aa=YP_009724390.1:p.Ser477Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0625;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=D614G;function_description=Lentiviral pseudotyped with the key mutations from 20A.EU2 lineage was neutralized slightly less than D614G in 10 convalescent sera from April 2020 infectees.;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22992	22992	.	+	.	"ID=ID_79;Name=S477N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=255;ao=17;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1430A;aa_name=p.S477N;hgvs_nt=NC_045512.2:g.1430G>A;hgvs_aa=YP_009724390.1:p.Ser477Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0625;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1;citation=Zhou et al. (2021);comb_mutation=L5F,T95I,D253G,D614G,A701V;function_description=Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed no significant  change in IC50 serum dilution concentration for 6 convalescent sera.;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	22992	22992	.	+	.	ID=ID_88;Name=S477N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=255;ao=17;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1430A;aa_name=p.S477N;hgvs_nt=NC_045512.2:g.1430G>A;hgvs_aa=YP_009724390.1:p.Ser477Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0625;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2021);comb_mutation=;function_description=Mixed bag of mild positive and negative changes in neutralization capability of all 4 convalescent sera tested. Against a wider panel of 16 convalescent plasma (no replicates), 10 show low neutralization.;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22992	22992	.	+	.	ID=ID_88;Name=S477N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=255;ao=17;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1430A;aa_name=p.S477N;hgvs_nt=NC_045512.2:g.1430G>A;hgvs_aa=YP_009724390.1:p.Ser477Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0625;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2021);comb_mutation=;function_description=Strong reduction in neutralization capability of all 4 convalescent sera tested (2 ablations).;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22992	22992	.	+	.	ID=ID_88;Name=S477N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=255;ao=17;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1430A;aa_name=p.S477N;hgvs_nt=NC_045512.2:g.1430G>A;hgvs_aa=YP_009724390.1:p.Ser477Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0625;function_category=ACE2 host variant dependency;source=https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1;citation=Barton et al. (2021);comb_mutation=;function_description=This mutation's measured interaction affinity with ACE2:p.S19P (0.03% minor allele frequency,  found almost exclusively in African/African-Americans in the GnomAD database) was significantly lower than the predicted value,  indicating that these mutations were not independent. This is consistent with the fact that the ACE2 residue S19  is adjacent to RBD residue S477 in the contact interface.;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22992	22992	.	+	.	"ID=ID_79;Name=S477N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=255;ao=17;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1430A;aa_name=p.S477N;hgvs_nt=NC_045512.2:g.1430G>A;hgvs_aa=YP_009724390.1:p.Ser477Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0625;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1;citation=Zhou et al. (2021);comb_mutation=L5F,T95I,D253G,D614G,A701V;function_description=Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed no significant change in IC50 serum dilution concentration for sera from BNT162b2 (Pzifer) or mRNA1273 (Moderna) vacinees collected 28 days following booster dose.;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	22992	22992	.	+	.	ID=ID_79;Name=S477N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=255;ao=17;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1430A;aa_name=p.S477N;hgvs_nt=NC_045512.2:g.1430G>A;hgvs_aa=YP_009724390.1:p.Ser477Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0625;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation=L5F,T95I,D253G,D614G,A701V;function_description=Neutralization efficiency (ID50) against B.1.526 reduced 2.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22992	22992	.	+	.	ID=ID_88;Name=S477N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=255;ao=17;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1430A;aa_name=p.S477N;hgvs_nt=NC_045512.2:g.1430G>A;hgvs_aa=YP_009724390.1:p.Ser477Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0625;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, Spike gene expression increased 0.06 fold;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22992	22992	.	+	.	ID=ID_88;Name=S477N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=255;ao=17;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1430A;aa_name=p.S477N;hgvs_nt=NC_045512.2:g.1430G>A;hgvs_aa=YP_009724390.1:p.Ser477Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0625;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is 0.22 kcal/mol (i.e. stabilizing relative to wild type);heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	22992	22992	.	+	.	"ID=ID_87;Name=S477N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=255;ao=17;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1430A;aa_name=p.S477N;hgvs_nt=NC_045512.2:g.1430G>A;hgvs_aa=YP_009724390.1:p.Ser477Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.0625;function_category=reinfection;source=https://doi.org/10.1016/j.ijid.2021.03.068;citation=Fournier et al. (2021);comb_mutation=D614G;function_description=11 cases of re-infection with the ""Marseille-4"" variant found within 1028 positive tests, where all of the earlier infections were from different strains. This lineage is also characterized by N:p.M234I:A376T;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=T cell evasion;source=https://science.sciencemag.org/content/early/2021/04/29/science.abh1282;citation=Reynolds et al. (2021);comb_mutation=;function_description=Analyzing responses to the E484K mutation seen in B.1.351 and P.1 variants, we noted that it did  not fall in a region predicted to bind the HLAII alleles tested (table S4). The mutation appeared  to have no substantial or differential impact on T cell responses.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1;citation=Sun et al. (2021);comb_mutation=;function_description=Complete loss of binding in ELISA by the variant against monoclonal antibody VH-Fc ab8;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41586-021-03412-7;citation=Collier et al. (2021);comb_mutation=;function_description=Of 50 mAbs tested, major loss of neutralization observed for S2N28, S2X615, S2N12, S2X192, S2H7, S2X16, S2X58, S2H70, S2X613, S2D19, S2N22, S2D32, S2H58, S2M11, S2D106, S2X30.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.04.19.440481v1;citation=Li et al. (2021);comb_mutation=;function_description=Monoclonal antibodies 13G9 and 58G6 maintain fairly high neutralization potency, compared to others interfacing with E484K.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2;citation=Gaebler et al. (2021);comb_mutation=;function_description=Ablates binding by class 2 mAbs such as C144 that directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2020);comb_mutation=;function_description=Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows high resistence to 4 antibodies,  and broad low level resistence against much of the rest of the panel.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=Resistent to all seven class 2 (Spike 'up' or 'down' conformation, RBD targeting) antibodies tested, with 10-fold  or greater reduction in neutralization (plus notable reudction in two unclassfied mAbs).;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=;function_description=Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384 and S2H58.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41586-021-03398-2;citation=Wang et al. (2021);comb_mutation=;function_description=Pseudotyped virus model ablates neutralization by RBD-directed mAbs 4-20, 2-4, 2-43, 2-30, 2-15, LY-Cov555, C121. Pseudotyped virus model impairs neutralization by RBD-directed mAb COV2-2196 (somewhat more than fully pseudotyped B.1.351 or live virus);heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=antibody epitope effects;source=https://science.sciencemag.org/content/371/6531/823;citation=Rappazzo et al. (2021);comb_mutation=;function_description=Massive reduction in binding efficiency vs wild type for mAb LY-CoV555.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_91;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=This variant appears twice in the experiments, with slightly different affinities (both ~1.2x decrease in binding relative to D614G)  using flow cytometry and ACE2 ectodomains-Fc portion IgG complex.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_78;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,L5F,T95I,D253G,A701V;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.526) showed a 1.78x increase  in binding (KD) relative to D614G, even though each variant independently decreases binding.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=Liu et al. (2021);comb_mutation=;function_description=Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=Tian et al. (2021);comb_mutation=;function_description=Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1;citation=Vogel et al. (2021);comb_mutation=;function_description=The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1;citation=Laffeber et al. (2021);comb_mutation=;function_description=RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1;citation=Ramanathan et al. (2021);comb_mutation=;function_description=Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=ACE2 receptor binding affinity;source=https://www.nature.com/articles/s41586-021-03412-7;citation=Collier et al. (2021);comb_mutation=;function_description=This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=Tian et al. (2021);comb_mutation=;function_description=Reported moderate increase in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=;function_description=Among the first selected variants in an in vitro evolution experiment for ACE2 binding.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, ACE2 binding affinity increased 0.06 fold;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_91;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1;citation=Ferriera et al (2021);comb_mutation=;function_description=This variant alone shows a ~5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing no change in infection rate amongst the cells.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=Liu et al. (2021);comb_mutation=;function_description=This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=Bamlanivimab (LY-CoV555) lost ~16x binding against this isolated mutation. Casirivimab lost ~16x binding against this isolated mutation.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_89;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=S477N;function_description=Bamlanivimab (LY-CoV555) lost ~10x binding against this double mutation. Tixagevimab lost ~16x binding against this double mutation.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1;citation=Schmidt et al. (2021);comb_mutation=;function_description=Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_91;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation=D614G;function_description=Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint];heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1;citation=Tang et al. (2021);comb_mutation=;function_description=As measured by surface plasmon resonance, RBD with the E484K mutation alone showed a mean 19.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=The only mutation in the B.1.351 lineage that appears to contribute to neutralization reduction (~1.7x across 10 convalescent sera from April 2020 infectees);heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	"ID=ID_78;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1;citation=Zhou et al. (2021);comb_mutation=L5F,T95I,D253G,D614G,A701V;function_description=Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.8x reduction in  IC50 serum dilution concentration for 6 convalescent sera.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation=;function_description=Average ~5-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	"ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1;citation=Zhou et al. (2021);comb_mutation=;function_description=Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.3x reduction in  IC50 serum dilution concentration for 6 convalescent sera.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2021);comb_mutation=;function_description=Remarkably, several of the E484 escape mutants were resistant to neutralization at the highest concentration (1:80 initial dilution) of all 4 convalescent sera tested (triplicate experiments). Against a wider panel of 16 convalescent plasma (no replicates), all but one show major resistance.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41586-021-03398-2;citation=Wang et al. (2021);comb_mutation=;function_description=The neutralizing activity of 15/20 convalescent sera was significantly lower against this pseudotyped virus model;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	"ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=convalescent plasma escape;source=https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf;citation=Cele et al. (2021);comb_mutation=;function_description=The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	"ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2020.12.28.424451;citation=Andreano et al. (2020);comb_mutation=;function_description=This mutation occurred in 100% of sequenced virions after 12 passages and led to a 4-fold decrease in convalescent plasma neutralization activity;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_91;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.42x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_78;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,L5F,T95I,D253G,A701V;function_description=This variant combination (representing lineage B.1.526) showed a 1.02x increase in Spike binding (relative  to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_91;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation=D614G;function_description=Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1084/jem.20202756;citation=Solfrosi et al. (2021);comb_mutation=;function_description=Neutralizing antibody titers of non-human primate sera after one or two doses of Ad26.COV2.S (Jannsen vaccine)  against the variants containing the E484K substitution in the RBD were present but reduced  (fold reduction between 3.357.78, 95% confidence interval all above twofold difference, one-sample t test).;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.21203%2Frs.3.rs-400230%2Fv1;citation=Ikegame et al. (2021);comb_mutation=;function_description=E484K pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. A cohort of 12 Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed a mean 2.8x decrease in neutralization effiacacy.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/S2666-5247(21;citation=Jangra et al. (2021);comb_mutation=;function_description=Human sera from 5 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) neutralized this variant 3.4x less relative to reference  USA-WA1/2020 strain. 8 convalescent plasma with weak IgG ELISA titre neutralized this variant 2.4x less relative to reference  USA-WA1/2020 strain. One plasma failed to neutralize at all. 11 convalescent plasma with moderate IgG ELISA titre neutralized this variant 4.2x less relative to reference  USA-WA1/2020 strain.  11 convalescent plasma with high IgG ELISA titre neutralized this variant 2.6x less relative to reference  USA-WA1/2020 strain.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_91;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1;citation=Ferreira et al. (2021);comb_mutation=;function_description=Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. E484K conferred a ten-fold reduction in neutralisation by vaccine sera.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	"ID=ID_78;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1;citation=Zhou et al. (2021);comb_mutation=L5F,T95I,D253G,D614G,A701V;function_description=Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.6x reduction in both IC50 serum dilution concentration for sera from 5 BNT162b2 (Pzifer) or 3 mRNA1273 (Moderna) vacinees collected 28 days following booster dose.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_78;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1;citation=Pegu et al (2021);comb_mutation=L5F,T95I,D253G,D614G,A701V;function_description=Detectable antibodies against B.1.526+E484K at various time points using pseudotyped lentivirus neutralization in Moderna vaccinee cohort: Day 43 100%, Day 209 88%.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_78;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L5F,T95I,D253G,D614G,A701V;function_description=2.3x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees);heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  ELISA tests show 10x reduced efficacy of a majority of isolated antibodies, but only a modest decrease for vaccine plasma overall.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=monoclonal antibody serial passage escape;source=http://dx.doi.org/10.1126/science.abd0831;citation=Baum et al. (2020);comb_mutation=;function_description=Escape variant 100% appearance in 2 passages against Regeneron monoclonal antibody REGN10989 @ 50ug/mL (99% after one passage);heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf;citation=Weisblum et al. (2020);comb_mutation=;function_description=Strong positive selection (up to 50% of supernatant sequences) after C121 monoclonal antibody assay, decreasing in subsequent passages Strong positive selection (up to 44% of supernatant sequences) after after one round of C144 monoclonal antibody passage, then waning on subsequent passages;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=monoclonal antibody serial passage escape;source=https://www.nature.com/articles/s41586-020-2852-1_reference.pdf?origin;citation=Barnes et al. (2020);comb_mutation=;function_description=The engineered mutation cause 10-fold or more increase in the disassociation constant with many monoclonal antibodies (C144/C002/C121/C104/C110).;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=;function_description=Mildly effective mutant against this position in the RBD for highly neutralizing COV2-2479 monoclonal antibody Effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;citation=Starr et al. (2021);comb_mutation=;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=Class 2 antibodies C627, C602, C671, C643, and class 2/3 antibody C603 selected for the emergence of the E484K mutation in vitro.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_90;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is -0.6 kcal/mol (i.e. destabilizing relative to wild type);heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_91;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23012	23012	.	+	.	ID=ID_78;Name=E484K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=18;ao=254;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G1450A;aa_name=p.E484K;hgvs_nt=NC_045512.2:g.1450G>A;hgvs_aa=YP_009724390.1:p.Glu484Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9338235294117647;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,L5F,T95I,D253G,A701V;function_description=This variant combination (representing lineage B.1.526) showed a 1.34x increase in Spike binding (relative  to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_92;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=immunosuppression variant emergence;source=https://www.medrxiv.org/content/10.1101/2021.05.08.21256775v1;citation=Landis et al. (2021);comb_mutation=;function_description=Studying 94 COVID-19 extended infection cases with genomics April 1 to October 17, 2020, one case developed 23 mutations in a 19 day period, including this combination in Spike.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_87;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=symptom prevalence;source=https://doi.org/10.1016/j.ijid.2021.03.068;citation=Fournier et al. (2021);comb_mutation=S477N;function_description=Compared to the clade 20A strains that predominated during phase 1 between March and May 2020, the Marseille-4 variant (characterized  by this mutation plus N:p.M234I:A376T) was associated with a lower frequency of cough, rhinitis, and olfactory and gustatory disorders.  By contrast, hypoxemia was more frequent in patients infected with the Marseille-4 variant.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_92;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_91;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=E484K;function_description=This variant appears twice in the experiments, with slightly different affinities (both ~1.2x decrease in binding relative to D614G)  using flow cytometry and ACE2 ectodomains-Fc portion IgG complex.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_93;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=A701V;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed essentially no change in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_77;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L5F;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.1x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_82;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=T95I;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.33x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_86;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D253G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.08x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_78;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L5F,T95I,D253G,E484K,A701V;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.526) showed a 1.78x increase  in binding (KD) relative to D614G, even though each variant independently decreases binding.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_92;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.07.012;citation=Li et al. (2020);comb_mutation=;function_description=In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_92;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=~4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_92;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_91;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=E484K;function_description=~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_87;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=S477N;function_description=Lentiviral pseudotyped with the key mutations from 20A.EU2 lineage was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing no significant change in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_92;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1;citation=Barrett et al. (2021);comb_mutation=;function_description=Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry);heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_92;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.nature.com/articles/s41467-020-19808-4;citation=Zhang et l. (2020);comb_mutation=;function_description=We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_92;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.nature.com/articles/s41467-021-21118-2;citation=Ozono et al. (2020);comb_mutation=;function_description=Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_92;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.7554/elife.65365;citation=Daniloski et al. (2021);comb_mutation=;function_description=The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing  endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2.  Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants,  the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_92;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=tissue specific neutralization;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation=;function_description=The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oralnasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_92;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=viral load;source=https://www.nature.com/articles/s41586-020-2895-3;citation=Plante et al. (2020);comb_mutation=;function_description=Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_83;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=outcome hazard ratio;source=https://www.medrxiv.org/content/10.1101/2021.08.04.21261596v1;citation=Yang et al. (2021);comb_mutation=T95I,D253G;function_description=B.1.526 (Iota) substantially increased IFR in older adults: by 46% (95% CI: 7.4  84%) among 45-64 year-olds,  82% (95% CI: 20  140%) among 65-74 year-olds, and 62% (95% CI: 45  80%) among 75+ during Nov 2020  Apr 2021,  compared to baseline IFR estimated for preexisting variants. [minimum clade defining mutations listed];heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_91;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation=E484K;function_description=Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint];heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_87;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=S477N;function_description=Lentiviral pseudotyped with the key mutations from 20A.EU2 lineage was neutralized slightly less than D614G in 10 convalescent sera from April 2020 infectees.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	"ID=ID_79;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1;citation=Zhou et al. (2021);comb_mutation=L5F,T95I,D253G,S477N,A701V;function_description=Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed no significant  change in IC50 serum dilution concentration for 6 convalescent sera.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23403	23403	.	+	.	"ID=ID_78;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1;citation=Zhou et al. (2021);comb_mutation=L5F,T95I,D253G,E484K,A701V;function_description=Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.8x reduction in  IC50 serum dilution concentration for 6 convalescent sera.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_91;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=E484K;function_description=1.42x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_93;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=A701V;function_description=1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_77;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L5F;function_description=No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_82;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=T95I;function_description=No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_86;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D253G;function_description=1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_78;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L5F,T95I,D253G,E484K,A701V;function_description=This variant combination (representing lineage B.1.526) showed a 1.02x increase in Spike binding (relative  to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_91;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation=E484K;function_description=Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_91;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=E484K;function_description=This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_92;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=;function_description=Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (911 days post-second dose of Pfizer) exhibited a robust  neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the  individuals who received one dose of vaccinationmean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was  obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700)  21 to 63 days post-onset.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	"ID=ID_79;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1;citation=Zhou et al. (2021);comb_mutation=L5F,T95I,D253G,S477N,A701V;function_description=Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed no significant change in IC50 serum dilution concentration for sera from BNT162b2 (Pzifer) or mRNA1273 (Moderna) vacinees collected 28 days following booster dose.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_79;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation=L5F,T95I,D253G,S477N,A701V;function_description=Neutralization efficiency (ID50) against B.1.526 reduced 2.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	"ID=ID_78;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1;citation=Zhou et al. (2021);comb_mutation=L5F,T95I,D253G,E484K,A701V;function_description=Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.6x reduction in both IC50 serum dilution concentration for sera from 5 BNT162b2 (Pzifer) or 3 mRNA1273 (Moderna) vacinees collected 28 days following booster dose.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_78;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1;citation=Pegu et al (2021);comb_mutation=L5F,T95I,D253G,E484K,A701V;function_description=Detectable antibodies against B.1.526+E484K at various time points using pseudotyped lentivirus neutralization in Moderna vaccinee cohort: Day 43 100%, Day 209 88%.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_78;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L5F,T95I,D253G,E484K,A701V;function_description=2.3x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees);heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_92;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=;function_description=Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9  days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_92;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.nature.com/articles/s41467-020-19808-4;citation=Zhang et al. (2020);comb_mutation=;function_description=Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	"ID=ID_92;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492024/;citation=Yurkovetskiy et al. (2020);comb_mutation=;function_description=CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23403	23403	.	+	.	"ID=ID_92;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.medrxiv.org/content/10.1101/2020.07.22.20159905v2;citation=Weissman et al. (2020);comb_mutation=;function_description=Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_92;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type);heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	"ID=ID_87;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://doi.org/10.1016/j.ijid.2021.03.068;citation=Fournier et al. (2021);comb_mutation=S477N;function_description=11 cases of re-infection with the ""Marseille-4"" variant found within 1028 positive tests, where all of the earlier infections were from different strains. This lineage is also characterized by N:p.M234I:A376T;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_91;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=E484K;function_description=1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_93;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=A701V;function_description=1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_77;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L5F;function_description=1.23x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_82;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=T95I;function_description=1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.02x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_86;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D253G;function_description=No significant change in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_78;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L5F,T95I,D253G,E484K,A701V;function_description=This variant combination (representing lineage B.1.526) showed a 1.34x increase in Spike binding (relative  to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23443	23443	.	+	.	ID=ID_94;Name=D627D;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=264;ao=8;dp=272;sample_size=280;Reference_seq=T;Variant_seq=C;nt_name=g.T1881C;aa_name=p.D627D;hgvs_nt=NC_045512.2:g.1881T>C;hgvs_aa=YP_009724390.1:p.Asp627Asp;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.029411764705882353;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23613	23613	.	+	.	ID=ID_95;Name=A684V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=269;ao=2;dp=271;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C2051T;aa_name=p.A684V;hgvs_nt=NC_045512.2:g.2051C>T;hgvs_aa=YP_009724390.1:p.Ala684Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007380073800738007;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23664	23664	.	+	.	ID=ID_93;Name=A701V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=14;ao=257;dp=271;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C2102T;aa_name=p.A701V;hgvs_nt=NC_045512.2:g.2102C>T;hgvs_aa=YP_009724390.1:p.Ala701Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.948339483394834;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed essentially no change in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23664	23664	.	+	.	ID=ID_78;Name=A701V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=14;ao=257;dp=271;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C2102T;aa_name=p.A701V;hgvs_nt=NC_045512.2:g.2102C>T;hgvs_aa=YP_009724390.1:p.Ala701Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.948339483394834;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,L5F,T95I,D253G,E484K;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.526) showed a 1.78x increase  in binding (KD) relative to D614G, even though each variant independently decreases binding.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23664	23664	.	+	.	ID=ID_96;Name=A701V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=14;ao=257;dp=271;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C2102T;aa_name=p.A701V;hgvs_nt=NC_045512.2:g.2102C>T;hgvs_aa=YP_009724390.1:p.Ala701Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.948339483394834;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23664	23664	.	+	.	"ID=ID_79;Name=A701V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=14;ao=257;dp=271;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C2102T;aa_name=p.A701V;hgvs_nt=NC_045512.2:g.2102C>T;hgvs_aa=YP_009724390.1:p.Ala701Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.948339483394834;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1;citation=Zhou et al. (2021);comb_mutation=L5F,T95I,D253G,S477N,D614G;function_description=Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed no significant  change in IC50 serum dilution concentration for 6 convalescent sera.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23664	23664	.	+	.	"ID=ID_78;Name=A701V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=14;ao=257;dp=271;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C2102T;aa_name=p.A701V;hgvs_nt=NC_045512.2:g.2102C>T;hgvs_aa=YP_009724390.1:p.Ala701Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.948339483394834;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1;citation=Zhou et al. (2021);comb_mutation=L5F,T95I,D253G,E484K,D614G;function_description=Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.8x reduction in  IC50 serum dilution concentration for 6 convalescent sera.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23664	23664	.	+	.	ID=ID_93;Name=A701V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=14;ao=257;dp=271;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C2102T;aa_name=p.A701V;hgvs_nt=NC_045512.2:g.2102C>T;hgvs_aa=YP_009724390.1:p.Ala701Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.948339483394834;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23664	23664	.	+	.	ID=ID_78;Name=A701V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=14;ao=257;dp=271;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C2102T;aa_name=p.A701V;hgvs_nt=NC_045512.2:g.2102C>T;hgvs_aa=YP_009724390.1:p.Ala701Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.948339483394834;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,L5F,T95I,D253G,E484K;function_description=This variant combination (representing lineage B.1.526) showed a 1.02x increase in Spike binding (relative  to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23664	23664	.	+	.	"ID=ID_79;Name=A701V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=14;ao=257;dp=271;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C2102T;aa_name=p.A701V;hgvs_nt=NC_045512.2:g.2102C>T;hgvs_aa=YP_009724390.1:p.Ala701Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.948339483394834;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1;citation=Zhou et al. (2021);comb_mutation=L5F,T95I,D253G,S477N,D614G;function_description=Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed no significant change in IC50 serum dilution concentration for sera from BNT162b2 (Pzifer) or mRNA1273 (Moderna) vacinees collected 28 days following booster dose.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23664	23664	.	+	.	ID=ID_79;Name=A701V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=14;ao=257;dp=271;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C2102T;aa_name=p.A701V;hgvs_nt=NC_045512.2:g.2102C>T;hgvs_aa=YP_009724390.1:p.Ala701Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.948339483394834;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation=L5F,T95I,D253G,S477N,D614G;function_description=Neutralization efficiency (ID50) against B.1.526 reduced 2.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23664	23664	.	+	.	"ID=ID_78;Name=A701V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=14;ao=257;dp=271;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C2102T;aa_name=p.A701V;hgvs_nt=NC_045512.2:g.2102C>T;hgvs_aa=YP_009724390.1:p.Ala701Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.948339483394834;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1;citation=Zhou et al. (2021);comb_mutation=L5F,T95I,D253G,E484K,D614G;function_description=Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.6x reduction in both IC50 serum dilution concentration for sera from 5 BNT162b2 (Pzifer) or 3 mRNA1273 (Moderna) vacinees collected 28 days following booster dose.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;"
NC_045512.2	.	snp	23664	23664	.	+	.	ID=ID_78;Name=A701V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=14;ao=257;dp=271;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C2102T;aa_name=p.A701V;hgvs_nt=NC_045512.2:g.2102C>T;hgvs_aa=YP_009724390.1:p.Ala701Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.948339483394834;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1;citation=Pegu et al (2021);comb_mutation=L5F,T95I,D253G,E484K,D614G;function_description=Detectable antibodies against B.1.526+E484K at various time points using pseudotyped lentivirus neutralization in Moderna vaccinee cohort: Day 43 100%, Day 209 88%.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23664	23664	.	+	.	ID=ID_78;Name=A701V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=14;ao=257;dp=271;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C2102T;aa_name=p.A701V;hgvs_nt=NC_045512.2:g.2102C>T;hgvs_aa=YP_009724390.1:p.Ala701Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.948339483394834;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=L5F,T95I,D253G,E484K,D614G;function_description=2.3x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees);heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23664	23664	.	+	.	ID=ID_96;Name=A701V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=14;ao=257;dp=271;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C2102T;aa_name=p.A701V;hgvs_nt=NC_045512.2:g.2102C>T;hgvs_aa=YP_009724390.1:p.Ala701Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.948339483394834;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is -0.33 kcal/mol (i.e. destabilizing relative to wild type);heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23664	23664	.	+	.	ID=ID_93;Name=A701V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=14;ao=257;dp=271;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C2102T;aa_name=p.A701V;hgvs_nt=NC_045512.2:g.2102C>T;hgvs_aa=YP_009724390.1:p.Ala701Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.948339483394834;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23664	23664	.	+	.	ID=ID_78;Name=A701V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=14;ao=257;dp=271;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C2102T;aa_name=p.A701V;hgvs_nt=NC_045512.2:g.2102C>T;hgvs_aa=YP_009724390.1:p.Ala701Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.948339483394834;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G,L5F,T95I,D253G,E484K;function_description=This variant combination (representing lineage B.1.526) showed a 1.34x increase in Spike binding (relative  to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	23731	23731	.	+	.	ID=ID_97;Name=T723T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=268;ao=3;dp=271;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C2169T;aa_name=p.T723T;hgvs_nt=NC_045512.2:g.2169C>T;hgvs_aa=YP_009724390.1:p.Thr723Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01107011070110701;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24073	24073	.	+	.	ID=ID_98;Name=Y837Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=226;ao=45;dp=271;sample_size=280;Reference_seq=T;Variant_seq=C;nt_name=g.T2511C;aa_name=p.Y837Y;hgvs_nt=NC_045512.2:g.2511T>C;hgvs_aa=YP_009724390.1:p.Tyr837Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.16605166051660517;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	24432	24432	.	+	.	ID=ID_99;Name=Q957R;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=257;ao=14;dp=271;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A2870G;aa_name=p.Q957R;hgvs_nt=NC_045512.2:g.2870A>G;hgvs_aa=YP_009724390.1:p.Gln957Arg;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05166051660516605;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25340	25340	.	+	.	ID=ID_100;Name=D1260N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=270;ao=2;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G3778A;aa_name=p.D1260N;hgvs_nt=NC_045512.2:g.3778G>A;hgvs_aa=YP_009724390.1:p.Asp1260Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007352941176470588;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25489	25489	.	+	.	ID=ID_101;Name=A33S;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=251;ao=21;dp=272;sample_size=280;Reference_seq=G;Variant_seq=T;nt_name=g.G97T;aa_name=p.A33S;hgvs_nt=NC_045512.2:g.97G>T;hgvs_aa=YP_009724391.1:p.Ala33Ser;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.07720588235294118;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25517	25517	.	+	.	ID=ID_102;Name=P42L;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=209;dp=209;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C125T;aa_name=p.P42L;hgvs_nt=NC_045512.2:g.125C>T;hgvs_aa=YP_009724391.1:p.Pro42Leu;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25563	25563	.	+	.	ID=ID_103;Name=Q57H;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=G;Variant_seq=T;nt_name=g.G171T;aa_name=p.Q57H;hgvs_nt=NC_045512.2:g.171G>T;hgvs_aa=YP_009724391.1:p.Gln57His;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25680	25680	.	+	.	ID=ID_104;Name=L96L;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=268;ao=4;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C288T;aa_name=p.L96L;hgvs_nt=NC_045512.2:g.288C>T;hgvs_aa=YP_009724391.1:p.Leu96Leu;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=SILENT;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.014705882352941176;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25958	25958	.	+	.	ID=ID_105;Name=Y189C;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=270;ao=2;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A566G;aa_name=p.Y189C;hgvs_nt=NC_045512.2:g.566A>G;hgvs_aa=YP_009724391.1:p.Tyr189Cys;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007352941176470588;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	25968	25968	.	+	.	ID=ID_106;Name=K192K;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=258;ao=14;dp=272;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A576G;aa_name=p.K192K;hgvs_nt=NC_045512.2:g.576A>G;hgvs_aa=YP_009724391.1:p.Lys192Lys;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=SILENT;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.051470588235294115;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	26152	26152	.	+	.	ID=ID_107;Name=G254R;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=262;ao=10;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G760A;aa_name=p.G254R;hgvs_nt=NC_045512.2:g.760G>A;hgvs_aa=YP_009724391.1:p.Gly254Arg;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03676470588235294;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	26681	26681	.	+	.	ID=ID_108;Name=F53F;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=235;ao=37;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C159T;aa_name=p.F53F;hgvs_nt=NC_045512.2:g.159C>T;hgvs_aa=YP_009724393.1:p.Phe53Phe;hgvs_alias=n/a;vcf_gene=M;mutation_type=SILENT;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.13602941176470587;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	26849	26849	.	+	.	ID=ID_109;Name=M109I;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=227;ao=45;dp=272;sample_size=280;Reference_seq=G;Variant_seq=T;nt_name=g.G327T;aa_name=p.M109I;hgvs_nt=NC_045512.2:g.327G>T;hgvs_aa=YP_009724393.1:p.Met109Ile;hgvs_alias=n/a;vcf_gene=M;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.16544117647058823;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27240	27240	.	+	.	ID=ID_110;Name=E13D;alias=n/a;gene=ORF6;protein_name=ORF6 protein;protein_symbol=ORF6;protein_id=YP_009724394.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=270;ao=2;dp=272;sample_size=280;Reference_seq=G;Variant_seq=T;nt_name=g.G39T;aa_name=p.E13D;hgvs_nt=NC_045512.2:g.39G>T;hgvs_aa=YP_009724394.1:p.Glu13Asp;hgvs_alias=n/a;vcf_gene=ORF6;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007352941176470588;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27384	27384	.	+	.	ID=ID_111;Name=D61D;alias=n/a;gene=ORF6;protein_name=ORF6 protein;protein_symbol=ORF6;protein_id=YP_009724394.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=235;ao=37;dp=272;sample_size=280;Reference_seq=T;Variant_seq=C;nt_name=g.T183C;aa_name=p.D61D;hgvs_nt=NC_045512.2:g.183T>C;hgvs_aa=YP_009724394.1:p.Asp61Asp;hgvs_alias=n/a;vcf_gene=ORF6;mutation_type=SILENT;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.13602941176470587;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27667	27667	.	+	.	ID=ID_112;Name=E92K;alias=n/a;gene=ORF7a;protein_name=ORF7a protein;protein_symbol=ORF7a;protein_id=YP_009724395.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=268;ao=4;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G274A;aa_name=p.E92K;hgvs_nt=NC_045512.2:g.274G>A;hgvs_aa=YP_009724395.1:p.Glu92Lys;hgvs_alias=n/a;vcf_gene=ORF7a;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.014705882352941176;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27689	27689	.	+	.	ID=ID_113;Name=P99L;alias=n/a;gene=ORF7a;protein_name=ORF7a protein;protein_symbol=ORF7a;protein_id=YP_009724395.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=269;ao=3;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C296T;aa_name=p.P99L;hgvs_nt=NC_045512.2:g.296C>T;hgvs_aa=YP_009724395.1:p.Pro99Leu;hgvs_alias=n/a;vcf_gene=ORF7a;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.011029411764705883;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27739	27739	.	+	.	ID=ID_114;Name=L116F;alias=n/a;gene=ORF7a;protein_name=ORF7a protein;protein_symbol=ORF7a;protein_id=YP_009724395.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=258;ao=14;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C346T;aa_name=p.L116F;hgvs_nt=NC_045512.2:g.346C>T;hgvs_aa=YP_009724395.1:p.Leu116Phe;hgvs_alias=n/a;vcf_gene=ORF7a;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.051470588235294115;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	complex	27847	27847	.	+	.	ID=ID_115;Name=SL31X;alias=n/a;gene=ORF7b;protein_name=ORF7b;protein_symbol=ORF7b;protein_id=YP_009725318.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=141;ao=3;dp=272;sample_size=280;Reference_seq=CAC;Variant_seq=GAT;nt_name=g.CAC92_94GAT;aa_name=p.SL31X;hgvs_nt=n/a;hgvs_aa=YP_009725318.1:p.SerLeu31Xaa;hgvs_alias=n/a;vcf_gene=ORF7b;mutation_type=;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.011029411764705883;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27847	27847	.	+	.	ID=ID_116;Name=L32F;alias=n/a;gene=ORF7b;protein_name=ORF7b;protein_symbol=ORF7b;protein_id=YP_009725318.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=141;ao=128;dp=272;sample_size=280;Reference_seq=CAC;Variant_seq=CAT;nt_name=g.C94T;aa_name=p.L32F;hgvs_nt=NC_045512.2:g.94C>T;hgvs_aa=YP_009725318.1:p.Leu32Phe;hgvs_alias=n/a;vcf_gene=ORF7b;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.47058823529411764;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27915	27915	.	+	.	ID=ID_117;Name=G8R;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=258;ao=14;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G22A;aa_name=p.G8R;hgvs_nt=NC_045512.2:g.22G>A;hgvs_aa=YP_009724396.1:p.Gly8Arg;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.051470588235294115;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27925	27925	.	+	.	ID=ID_118;Name=T11I;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=272;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C32T;aa_name=p.T11I;hgvs_nt=NC_045512.2:g.32C>T;hgvs_aa=YP_009724396.1:p.Thr11Ile;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	27945	27945	.	+	.	ID=ID_119;Name=Q18X;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=268;ao=4;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.Q18X;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009724396.1:p.Gln18Xaa;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=NONSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.014705882352941176;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28086	28086	.	+	.	ID=ID_120;Name=A65S;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=267;ao=5;dp=272;sample_size=280;Reference_seq=G;Variant_seq=T;nt_name=g.G193T;aa_name=p.A65S;hgvs_nt=NC_045512.2:g.193G>T;hgvs_aa=YP_009724396.1:p.Ala65Ser;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01838235294117647;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	del	28270	28270	.	+	.	ID=ID_121;Name=g.-3delA;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=2;ao=266;dp=268;sample_size=280;Reference_seq=TA;Variant_seq=T;nt_name=g.-3delA;aa_name=;hgvs_nt=NC_045512.2:g.-3del;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=N;mutation_type=;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9925373134328358;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28311	28311	.	+	.	ID=ID_122;Name=P13L;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=258;ao=14;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C38T;aa_name=p.P13L;hgvs_nt=NC_045512.2:g.38C>T;hgvs_aa=YP_009724397.2:p.Pro13Leu;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.051470588235294115;function_category=T cell evasion;source=https://www.biorxiv.org/content/10.1101/2021.04.08.438904v1;citation=de Silva et al. (2021);comb_mutation=;function_description=Variant causes complete loss of T cell line responsiveness to B*27:05-restricted CD8+ N epitope QRNAPRITF 1-17(2,13).;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28311	28311	.	+	.	ID=ID_122;Name=P13L;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=258;ao=14;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C38T;aa_name=p.P13L;hgvs_nt=NC_045512.2:g.38C>T;hgvs_aa=YP_009724397.2:p.Pro13Leu;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.051470588235294115;function_category=homoplasy;source=https://www.biorxiv.org/content/10.1101/2021.05.19.444774v1;citation=Borges et al. (2021);comb_mutation=;function_description=In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation appears convergent.;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28313	28313	.	+	.	ID=ID_123;Name=R14C;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=270;ao=2;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C40T;aa_name=p.R14C;hgvs_nt=NC_045512.2:g.40C>T;hgvs_aa=YP_009724397.2:p.Arg14Cys;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007352941176470588;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28531	28531	.	+	.	ID=ID_124;Name=Y86Y;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=137;ao=135;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C258T;aa_name=p.Y86Y;hgvs_nt=NC_045512.2:g.258C>T;hgvs_aa=YP_009724397.2:p.Tyr86Tyr;hgvs_alias=n/a;vcf_gene=N;mutation_type=SILENT;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4963235294117647;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28734	28734	.	+	.	ID=ID_125;Name=N154I;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=267;ao=5;dp=272;sample_size=280;Reference_seq=A;Variant_seq=T;nt_name=g.A461T;aa_name=p.N154I;hgvs_nt=NC_045512.2:g.461A>T;hgvs_aa=YP_009724397.2:p.Asn154Ile;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01838235294117647;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28869	28869	.	+	.	ID=ID_126;Name=P199L;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=14;ao=258;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C596T;aa_name=p.P199L;hgvs_nt=NC_045512.2:g.596C>T;hgvs_aa=YP_009724397.2:p.Pro199Leu;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9485294117647058;function_category=RNA binding;source=https://www.biorxiv.org/content/10.1101/2021.08.05.455082v1;citation=Syed et al. (2021);comb_mutation=;function_description=Northern blot analysis of novel mutant virus-like-particles (VLPs) shows increase in RNA content with this mutation, suggesting that it improves virus particle production (requisite RNA packaging signal binding site in nsp15/16 boundary is included in the VLP).;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28879	28879	.	+	.	ID=ID_127;Name=S202R;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=258;ao=14;dp=272;sample_size=280;Reference_seq=T;Variant_seq=G;nt_name=g.T606G;aa_name=p.S202R;hgvs_nt=NC_045512.2:g.606T>G;hgvs_aa=YP_009724397.2:p.Ser202Arg;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.051470588235294115;function_category=RNA binding;source=https://www.biorxiv.org/content/10.1101/2021.08.05.455082v1;citation=Syed et al. (2021);comb_mutation=;function_description=Northern blot analysis of novel mutant virus-like-particles (VLPs) shows major increase in RNA content with this mutation, suggesting that  it improves virus particle production (requisite RNA packaging signal binding site in nsp15/16 boundary is included in the VLP).;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	28975	28975	.	+	.	ID=ID_128;Name=M234I;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=14;ao=258;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G702A;aa_name=p.M234I;hgvs_nt=NC_045512.2:g.702G>A;hgvs_aa=YP_009724397.2:p.Met234Ile;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9485294117647058;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29000	29000	.	+	.	ID=ID_129;Name=G243C;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=227;ao=42;dp=269;sample_size=280;Reference_seq=G;Variant_seq=T;nt_name=g.G727T;aa_name=p.G243C;hgvs_nt=NC_045512.2:g.727G>T;hgvs_aa=YP_009724397.2:p.Gly243Cys;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.15613382899628253;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29171	29171	.	+	.	ID=ID_130;Name=H300Y;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=268;ao=4;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C898T;aa_name=p.H300Y;hgvs_nt=NC_045512.2:g.898C>T;hgvs_aa=YP_009724397.2:p.His300Tyr;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.014705882352941176;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29200	29200	.	+	.	ID=ID_131;Name=P309P;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=267;ao=5;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C927T;aa_name=p.P309P;hgvs_nt=NC_045512.2:g.927C>T;hgvs_aa=YP_009724397.2:p.Pro309Pro;hgvs_alias=n/a;vcf_gene=N;mutation_type=SILENT;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.01838235294117647;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29257	29257	.	+	.	ID=ID_132;Name=G328G;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=270;ao=2;dp=272;sample_size=280;Reference_seq=A;Variant_seq=C;nt_name=g.A984C;aa_name=p.G328G;hgvs_nt=NC_045512.2:g.984A>C;hgvs_aa=YP_009724397.2:p.Gly328Gly;hgvs_alias=n/a;vcf_gene=N;mutation_type=SILENT;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007352941176470588;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29370	29370	.	+	.	ID=ID_133;Name=T366I;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=265;ao=7;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C1097T;aa_name=p.T366I;hgvs_nt=NC_045512.2:g.1097C>T;hgvs_aa=YP_009724397.2:p.Thr366Ile;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.025735294117647058;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29449	29449	.	+	.	ID=ID_134;Name=V392V;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=270;ao=2;dp=272;sample_size=280;Reference_seq=G;Variant_seq=T;nt_name=g.G1176T;aa_name=p.V392V;hgvs_nt=NC_045512.2:g.1176G>T;hgvs_aa=YP_009724397.2:p.Val392Val;hgvs_alias=n/a;vcf_gene=N;mutation_type=SILENT;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007352941176470588;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29543	29543	.	+	.	ID=ID_135;Name=g.G-15T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=141;ao=131;dp=272;sample_size=280;Reference_seq=G;Variant_seq=T;nt_name=g.G-15T;aa_name=;hgvs_nt=NC_045512.2:g.15G>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=ORF10;mutation_type=;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.48161764705882354;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29586	29586	.	+	.	ID=ID_136;Name=P10L;alias=n/a;gene=ORF10;protein_name=ORF10 protein;protein_symbol=ORF10;protein_id=YP_009725255.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=270;ao=2;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C29T;aa_name=p.P10L;hgvs_nt=NC_045512.2:g.29C>T;hgvs_aa=YP_009725255.1:p.Pro10Leu;hgvs_alias=n/a;vcf_gene=ORF10;mutation_type=MISSENSE;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007352941176470588;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29715	29715	.	+	.	ID=ID_137;Name=g.G29715A;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=141;ao=131;dp=272;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G29715A;aa_name=;hgvs_nt=NC_045512.2:g.29715G>A;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=intergenic;mutation_type=;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.48161764705882354;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29732	29732	.	+	.	ID=ID_138;Name=g.C29732T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=246;ao=26;dp=272;sample_size=280;Reference_seq=C;Variant_seq=T;nt_name=g.C29732T;aa_name=;hgvs_nt=NC_045512.2:g.29732C>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=intergenic;mutation_type=;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.09558823529411764;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	del	29737	29737	.	+	.	ID=ID_139;Name=g.GCCACGCGGAGTACGATCGAGTGT29737G;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=127;ao=9;dp=255;sample_size=280;Reference_seq=GCCACGCGGAGTACGATCGAGTGT;Variant_seq=G;nt_name=g.GCCACGCGGAGTACGATCGAGTGT29737G;aa_name=;hgvs_nt=n/a;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=intergenic;mutation_type=;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.03529411764705882;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29737	29737	.	+	.	ID=ID_140;Name=g.GCCACGCGGAGTACGATCGAGTGT29737TCCACGCGGAGTACGATCGAGTGT;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=127;ao=119;dp=255;sample_size=280;Reference_seq=GCCACGCGGAGTACGATCGAGTGT;Variant_seq=TCCACGCGGAGTACGATCGAGTGT;nt_name=g.GCCACGCGGAGTACGATCGAGTGT29737TCCACGCGGAGTACGATCGAGTGT;aa_name=;hgvs_nt=n/a;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=intergenic;mutation_type=;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.4666666666666667;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29764	29764	.	+	.	ID=ID_141;Name=g.G29764T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=133;ao=1;dp=134;sample_size=280;Reference_seq=G;Variant_seq=T;nt_name=g.G29764T;aa_name=;hgvs_nt=NC_045512.2:g.29764G>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=intergenic;mutation_type=;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.007462686567164179;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29781	29781	.	+	.	ID=ID_142;Name=g.G29781A;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=94;ao=1;dp=95;sample_size=280;Reference_seq=G;Variant_seq=A;nt_name=g.G29781A;aa_name=;hgvs_nt=NC_045512.2:g.29781G>A;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=intergenic;mutation_type=;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.010526315789473684;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
NC_045512.2	.	snp	29815	29815	.	+	.	ID=ID_143;Name=g.A29815G;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=94;ao=1;dp=95;sample_size=280;Reference_seq=A;Variant_seq=G;nt_name=g.A29815G;aa_name=;hgvs_nt=NC_045512.2:g.29815A>G;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=intergenic;mutation_type=;viral_lineage=B.1.526;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.010526315789473684;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Iota;variant_type=VOI;voi_designation_date=24-Mar-2021;voc_designation_date=;vum_designation_date=;status=de_escalated;
